Immunocellular Therapeutics Stock Earnings Per Share
ImmunoCellular Therapeutics fundamentals help investors to digest information that contributes to ImmunoCellular Therapeutics' financial success or failures. It also enables traders to predict the movement of ImmunoCellular Pink Sheet. The fundamental analysis module provides a way to measure ImmunoCellular Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoCellular Therapeutics pink sheet.
ImmunoCellular |
ImmunoCellular Therapeutics Company Earnings Per Share Analysis
ImmunoCellular Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current ImmunoCellular Therapeutics Earnings Per Share | 28.91 X |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, ImmunoCellular Therapeutics has an Earnings Per Share of 28.91 times. This is 245.4% higher than that of the Biotechnology sector and notably lower than that of the Health Care industry. The earnings per share for all United States stocks is notably lower than that of the firm.
ImmunoCellular Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.ImmunoCellular Therapeutics is currently under evaluation in earnings per share category among its peers.
ImmunoCellular Fundamentals
Return On Equity | -23.12 | ||||
Return On Asset | -4.4 | ||||
Current Valuation | (1.69 M) | ||||
Shares Outstanding | 4.19 M | ||||
Shares Owned By Insiders | 94.96 % | ||||
Number Of Shares Shorted | 165.95 K | ||||
Price To Earning | 0.02 X | ||||
Price To Book | 0.35 X | ||||
EBITDA | (6.07 M) | ||||
Net Income | (5.15 M) | ||||
Cash And Equivalents | 933.15 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 2.78 M | ||||
Debt To Equity | 0.39 % | ||||
Current Ratio | 1.51 X | ||||
Book Value Per Share | (0.03) X | ||||
Cash Flow From Operations | (2.31 M) | ||||
Short Ratio | 4.13 X | ||||
Earnings Per Share | 28.91 X | ||||
Target Price | 5.0 | ||||
Beta | 1.03 | ||||
Market Capitalization | 2.21 M | ||||
Total Asset | 30.08 M | ||||
Retained Earnings | (74.14 M) | ||||
Working Capital | 22.29 M | ||||
Current Asset | 24.56 M | ||||
Current Liabilities | 2.27 M | ||||
Z Score | -2.8 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Stocks Directory Find actively traded stocks across global markets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |